Aegon reports loss in first-half results
 
                Aegon reports loss in first-half results | Insurance Business America
Life & Health
Aegon reports loss in first-half results
CEO shines spotlight on improved figures
Life & Health
                            By
                                Terry Gangcuangco
                        
International financial services group Aegon has published its financial results for the first half of 2023.
According to the Netherlands-headquartered business, it posted a net loss worth €199 million in the period. During the same half-year span in 2022, the group enjoyed a positive net result of €46 million.
	
		
			
Source
			
			
H1 2023
			
			
H1 2022
			
		
	
	
		
			
Americas
			
			
€628 million
			
			
€605 million
			
		
		
			
United Kingdom
			
			
€111 million
			
			
€93 million
			
		
		
			
International
			
			
€95 million
			
			
€87 million
			
		
		
			
Asset management
			
			
€74 million
			
			
€117 million
			
		
		
			
Holding and other activities
			
			
€(91 million)
			
			
€(107 million)
			
		
		
			
Operating result
			
			
€818 million
			
			
€796 million
			
		
	
Lifting the lid on the numbers, chief executive Lard Friese said: “Our operating result increased by 3% compared with the same period in 2022, and reflects improved results in all insurance units while asset management was negatively impacted by a challenging market environment.
“Our net result was a loss of €199 million, and reflects previously announced items in the US that will position us well for future growth. Our operating capital generation was strong, driven largely by our US business. The capital ratios of our main units remained above their respective operating levels in the first half of 2023.
“These results provide a solid basis to raise the interim dividend by 3 eurocents compared with the 2022 interim dividend to 14 eurocents per share.”
What do you think about this story? Share your thoughts in the comments below.
Related Stories
Keep up with the latest news and events
Join our mailing list, it’s free!
                
 
                       
                       
                       
                       
                      